2篇
您的检索式：作者名="Manke Guan"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The global registry of COVID-19 clinical trials: indicating the design of traditional Chinese medicine clinical trials显示文摘Objective:To analyze the registration information of Corona Virus Disease 2019(COVID-19)related clinical trials from all the clinical trial registry accepted by the International Committee of Medical Journal Editors(ICMJE).Methods:All the database of ICMJE-accepted clinical trial registry platform were searched for COVID-19 related clinical trials that registered from December 8,2019 to February 19,2020.Results:All the database totally contained data of 209 COVID-19 related clinical trials,including 66(31.6%)traditional Chinese medicine(TCM)related studies and 143(68.4%)non-TCM related studies.176(84.2%)clinical trials were registered in ChiCTR,as 33(15.8%)were registered in ClinicalTrials.gov.There were 152(72.7%)intervention trials,including 9(4.3%in total)preventive trials,136(65.1%in total)therapeutic trials and 7(3.3%in total)convalescent trials.Conclusion:At the present stage,clinical studies are still aiming at exploring the effective treatment of COVID-19,and the existing treatments need more high-quality clinical evidence supporting.Traditional Chinese medicine may have played an important role in all stages of the epidemic preventing and control,and the enthusiasm of carrying out scientific research has also been greatly improved.The relevant policies of clinical trial registration should be popularized among researchers,including traditional Chinese medicine researchers.And the methodological quality of clinical trials’design urges improving. | Xuxu Wei Mengzhu Zhao Chen Zhao Xiaoyu Zhang Ruijin Qiu Yiyi Lin Yang Sun Manke Guan Hongcai Shang | 2020 | TMR Modern Herbal Medicine2020，3，3： | 1 |
| 2 | Wenxin granule for cardiac arrhythmia: an overview of systematic reviews显示文摘目的:对稳心颗粒治疗心律失常的系统评价/meta分析进行再评价,为临床应用提供证据;分析目前研究中存在的问题,为研究者提供可能的优先研究主题。方法:从8 个数据库中检索稳心颗粒治疗心律失常的系统评价。分别用AMSTAR和GRADE评估系统评价的方法学质量和证据质量。结果:共纳入1 9 项系统评价,涉及52, 9 0 5 个参与者。AMSTAR评分3-10分,平均6 .5 分,中位数为6 分, 9 (9/19, 47.37°%)项系统评价的AMSTAR得分大于7 分,对其中的6 项研究采用GRADE评估其证据质量。结果显示,所有研究的证据质量都在极低和低之间,无中、高质量证存在。从结局指标报告来看,没有系统评价评估终点指标,虽然有部分研究报告了不良反应/事件,但很少有研究进行因果关系判断。系统评价结局指标矩阵显示,结局指标报告存在明显的异质性及不完全报告的情况,导致有些研究不能进行m eta分析。同时,一些原始研究由于结局指标报告不合理而被不能纳入系统评价(如未报告相关结局指标,治疗时间不合适/不清楚,数据不完全或无法提取)。结论:稳心颗粒治疗心律失常的疗效和安全性证据有限,未来需要更多的高质量R C T s和系统评价提供证据。在未来的研究中,有必要构建心律失常核心指标集,以提高结局指标报告水平,减少由于结局指标报告不合理而造成的浪费。 | Ruijin Qiu Changming Zhong Huichan Yuan Xiaoyi Tang Ya Huang Tianmai He Songjie Han Manke Guan Min Li Jiayuan Hu Xiaoyu Zhang Jing Chen Hongcai Shang | 2019 | TMR Modern Herbal Medicine2019，2，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员